Pillar · Biotech Investing
Biotech Due Diligence Checklist: How to Evaluate a Drug Pipeline and Probability of Approval
Most biotech investors skip due diligence and pay the price. This step-by-step checklist walks you through everything yo...
Start here
Pillar · Clinical Readouts
How to Read Biotech Clinical Trial Data: Phase 1, 2, 3 Results Explained for Investors
Clinical trial data is the single most important factor in biotech investing, but most investors struggle to read it. Th...
FDA & PDUFA Calendar
EYP-1901 Phase 3 in nAMD: Biotech Catalysts Sep 21, 2026
As of September 21, 2026, we identify crucial biotech catalysts to watch, including IGALMI® and EYP-1901, shaping the future of treatments....
Clinical Readouts
Sabirnetug in Alzheimer Disease: Phase 2 and 3 Readouts Sep 14, 2026
On September 16, 2026, we analyze key phase 3 readouts for ALGS, CHRS, and ABOS, focusing on upcoming clinical trial results and market impacts....
FDA & PDUFA Calendar
SIL204 Phase 2/3 in Pancreatic Cancer: Biotech Catalysts Sep 14, 2026
As of September 14, 2026, investors should closely track upcoming biotech catalysts, including SIL204 and IGALMI, for potential market impact....
Therapeutic Areas
The Most Crowded Drug Targets in Biotech: 19 Companies Are Chasing CD19
19 biotechs are chasing CD19 and the median is worth $600M. 547 of 675 molecular targets have just one company on them....
FDA & PDUFA Calendar
IGALMI PDUFA and Namodenoson Data: Catalysts Sep 7
On November 14, 2026, IGALMI's approval decision could reshape agitation treatment in psychiatry. Explore pivotal biotech catalysts to watch....
Therapeutic Areas
Biotech Companies by Disease: $672B Across 299 Indications, 198 Uncontested
198 of 299 diseases have exactly one US-listed biotech developing a drug for them. The crowded ones carry the cheapest companies....
FDA & PDUFA Calendar
FDA Calendar September 2026: A Critical Look at Upcoming Approvals
September 2026 brings significant PDUFA dates, including Zidesamtinib and Ameluz®PDT. Here's what investors need to know....
FDA & PDUFA Calendar
Gossamer Seralutinib in PAH: Catalysts Aug 31 2026
GOSS's seralutinib (GB002) targets PAH with a 58% approval probability. Explore catalysts including PDUFA dates and market implications for 2026....
Catalyst Analysis
Biotech Stocks Hedge Funds Are Buying: $127.3B Across 520 Names, Q2 2026
44 biotech specialist funds hold a record $127.3B across 520 companies, the fewest ever. One ownership signal clears significance, and it is a negative one....